<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="75a4ea70-7ec8-4c24-87c9-fa3feb68af41"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <br/>
These highlights do not include all the information needed to use Fluocinolone Acetonide Topical Oil, 0.01% (Body Oil) safely and effectively. See full prescribing information for Fluocinolone Acetonide Topical Oil, 0.01%.
 <br/>
      <br/>
Fluocinolone Acetonide Topical Oil, 0.01% (Body Oil)
 <br/>
For topical use only
 <br/>
Initial U.S. Approval: 1988
<br/>
      <br/>NDC 64980-331-04<br/>
      <br/>For Topical Use Only - Not for Oral, Ophthalmic, or Intravaginal Use<br/>
   </title>
   <effectiveTime value="20250423"/>
   <setId root="f45b0ef2-1702-4d21-8ac8-774769304595"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="116880195" root="1.3.6.1.4.1.519.1"/>
            <name>Rising Pharma Holdings, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="116880195"/>
                  <name>Rising Pharma Holdings, Inc.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="053510459"/>
                        <name>Lyne Laboratories, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="64980-331" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3e4f5d13-a92f-4b41-81c7-e13423505779"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250423"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64980-331" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Fluocinolone Acetonide<suffix>Oil</suffix>
                        </name>
                        <formCode code="C42965" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OIL"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Fluocinolone Acetonide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0RE8K4LNJS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL MYRISTATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="N6K5787QVP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIGHT MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7L6R1SQ6M0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLETH-2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5TL50QU0W4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEANUT OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.11"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FLUOCINOLONE ACETONIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FLUOCINOLONE ACETONIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="118.28" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64980-331-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20160718"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203377" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160718"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s01">
               <id root="b984e634-fbca-483b-82ee-577ac094448c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fluocinolone Acetonide Topical Oil, 0.01% is a corticosteroid indicated for the</paragraph>
                        <list listType="unordered">
                           <item>topical treatment of atopic dermatitis in adult patients (<linkHtml href="#s01.1">1.1</linkHtml>)
         
 
    </item>
                           <item>topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks (<linkHtml href="#s01.2">1.2</linkHtml>)
         
 
    </item>
                        </list>
                        <paragraph>Limitations of Use:</paragraph>
                        <list listType="unordered">
                           <item>Apply the least amount to cover affected areas.<br/>Discontinue when disease is controlled. (<linkHtml href="#s01.3">1.3</linkHtml>) 
         
 
    </item>
                           <item>Do not use in the diaper area. (<linkHtml href="#s01.3">1.3</linkHtml>)
         
 
    </item>
                           <item>Do not use on the face, axillae, or groin. (<linkHtml href="#s01.3">1.3</linkHtml>, <linkHtml href="#s06.2">6.2</linkHtml>, <linkHtml href="#s08.4">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s01.1">
                     <id root="8d76edc0-5bc8-4c02-850f-a8569fb1d7b4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Adult Patients with Atopic Dermatitis</title>
                     <text>
                        <paragraph>Fluocinolone acetonide topical oil, 0.01% is indicated for the topical treatment of atopic dermatitis in adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s01.2">
                     <id root="577c8eb2-820b-47a3-a97c-27d0a6d0b965"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Pediatric Patients with Atopic Dermatitis</title>
                     <text>
                        <paragraph>Fluocinolone acetonide topical oil, 0.01% is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients, 3 months and older for up to 4 weeks. Safety and effectiveness in pediatric patients younger than 3 months of age have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s01.3">
                     <id root="e8ac990c-d4e8-4ee2-9ff8-532d8c98c956"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Limitations of Use</title>
                     <text>
                        <paragraph>Apply the least amount of fluocinolone acetonide topical oil, 0.01% needed to cover the affected areas. As with other corticosteroids, fluocinolone acetonide topical oil, 0.01% should be discontinued when control of disease is achieved. Contact the physician if no improvement is seen within 2 weeks. Fluocinolone acetonide topical oil, 0.01% should not be applied to the diaper area; diapers or plastic pants may constitute occlusive use.<br/>Fluocinolone acetonide topical oil, 0.01% should not be used on the face, axillae, or groin unless directed by the physician. Application to intertriginous areas should be avoided due to the increased risk of local adverse reactions.<content styleCode="italics">[see <linkHtml href="#s06">Adverse Reactions (6)</linkHtml> and <linkHtml href="#s08.4">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s02">
               <id root="66c6c34a-96aa-4a83-bf53-16442458b3d0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Fluocinolone acetonide topical oil, 0.01% is not for oral, ophthalmic, or intravaginal use. <content styleCode="bold">The dosing of fluocinolone acetonide topical oil, 0.01%  is different for adult and pediatric patients.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fluocinolone Acetonide Topical Oil, 0.01% is not for oral, ophthalmic, or intravaginal use. (<linkHtml href="#s02">2</linkHtml>)</paragraph>
                        <list listType="unordered">
                           <item>Adult patients: Apply to affected areas 3 times daily. (<linkHtml href="#s02.1">2.1</linkHtml>)</item>
                           <item>Pediatric patients: Moisten skin and apply to affected areas twice daily for up to 4 weeks. (<linkHtml href="#s02.2">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s02.1">
                     <id root="e88ed9b3-a427-49dd-a7c7-c43b9463cdd2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Adult Patients with Atopic Dermatitis</title>
                     <text>
                        <paragraph>Apply fluocinolone acetonide topical oil, 0.01% as a thin film to the affected areas <content styleCode="underline">three times daily.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s02.2">
                     <id root="7ce9c5ef-898c-4834-afbe-dc7747e7df4a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Pediatric Patients with Atopic Dermatitis</title>
                     <text>
                        <paragraph>Moisten skin and apply fluocinolone acetonide topical oil, 0.01% as a thin film to the affected areas <content styleCode="underline">twice daily for up to four weeks.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s03">
               <id root="a4ac6403-5db0-4372-b5d3-105a035eb4d5"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Fluocinolone Acetonide Topical Oil, 0.01% (Body Oil) is supplied in bottles containing 4 fluid ounces.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fluocinolone Acetonide Topical Oil, 0.01% (Body Oil) is supplied in bottles containing 4 fluid ounces. (<linkHtml href="#s03">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s04">
               <id root="2016d4c7-0f1b-4c37-8511-885747c5e264"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20250423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#s04">4</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s05">
               <id root="4a784b38-b394-43fb-9331-9a80425a5ab5"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Topical corticosteroids can produce reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. (<linkHtml href="#s05.1">5.1</linkHtml>)</item>
                           <item>Systemic absorption may require evaluation for hypothalamic-pituitary-adrenal (HPA) axis suppression. (<linkHtml href="#s05.1">5.1</linkHtml>)</item>
                           <item>Modify use should HPA axis suppression develop. (<linkHtml href="#s05.1">5.1</linkHtml>)</item>
                           <item>Potent corticosteroids use on large areas, prolonged use or occlusive use may increase systemic absorption. (<linkHtml href="#s05.1">5.1</linkHtml>)</item>
                           <item>Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be more likely with occlusive use or more potent corticosteroids. (<linkHtml href="#s05.2">5.2</linkHtml>, <linkHtml href="#s05.3">5.3</linkHtml>, <linkHtml href="#s06.1">6.1</linkHtml>) </item>
                           <item>Children may be more susceptible to systemic toxicity from equivalent doses. (<linkHtml href="#s05.1">5.1</linkHtml>,  <linkHtml href="#s08.4">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s05.1">
                     <id root="23f04666-e475-438c-a5ac-a5722fceaf19"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypothalamic-Pituitary-Adrenal Axis Suppression</title>
                     <text>
                        <paragraph>Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Cushing’s syndrome, hyperglycemia, and glucosuria can also be produced by systemic absorption of topical corticosteroids.</paragraph>
                        <paragraph>Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression.  The ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression.</paragraph>
                        <paragraph>If HPA axis suppression is documented, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid.</paragraph>
                        <paragraph>Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids.</paragraph>
                        <paragraph>Conditions which increase systemic absorption include the use of more potent corticosteroids, use over large surface areas, use over prolonged periods, and use of occlusive dressings.  Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids.</paragraph>
                        <paragraph>Children may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. <content styleCode="italics">[See <linkHtml href="#s08.4">Use in Specific Populations (8.4)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s05.2">
                     <id root="9b694c4a-b71c-48da-9615-490581874c7a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Local Adverse Reactions with Topical Corticosteroids</title>
                     <text>
                        <paragraph>Local adverse reactions may occur with use of topical corticosteroids and may be more likely to occur with occlusive use, prolonged use or use of higher potency corticosteroids. Some local adverse reactions may be irreversible. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. <content styleCode="italics">[See <linkHtml href="#s06.1">Adverse Reactions (6.1)</linkHtml>]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s05.3">
                     <id root="f0a0b12c-07cf-4683-b0de-c556411de871"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Allergic Contact Dermatitis with Topical Corticosteroids</title>
                     <text>
                        <paragraph>Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a <content styleCode="italics">failure to heal</content> rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s05.4">
                     <id root="6522d560-d053-4e34-bce1-b96b901e98af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Concomitant Skin Infections</title>
                     <text>
                        <paragraph>Concomitant skin infections should be treated with an appropriate antimicrobial agent. If the infection persists unchanged, fluocinolone acetonide topical oil, 0.01% should be discontinued until the infection has been adequately treated.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s05.5">
                     <id root="eafba0cf-9ba2-4371-815b-ebc7f0f96e18"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Use in Peanut-Sensitive Individuals</title>
                     <text>
                        <paragraph>Physicians should use caution in prescribing fluocinolone acetonide topical oil, 0.01% for peanut-sensitive individuals. <content styleCode="italics">[See <linkHtml href="#s11">Description (11)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>Should signs of hypersensitivity present (wheal and flare reactions, pruritus, or other manifestations), or should disease exacerbations occur, fluocinolone acetonide topical oil, 0.01% should be discontinued immediately and appropriate therapy instituted.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s06">
               <id root="487362d4-1f76-4ee2-977d-6e55aab91875"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥5%) were cough (20%), rhinorrhea (13%), pyrexia (10%), telangiectasia (7%), nasopharyngitis (7%), and hypopigmentation (7%). (<linkHtml href="#s06">6</linkHtml>)<br/>
                           <br/>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s06.1">
                     <id root="f1900e27-d181-49a5-962c-4aebc675a74d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Studies Experience: Evaluation of Facial Use in Pediatric Subjects</title>
                     <text>
                        <paragraph>An open-label study was conducted in 58 children with moderate to severe atopic dermatitis (2 to 12 years old) to evaluate the safety of fluocinolone acetonide topical oil, 0.01% when applied to the face twice daily for 4 weeks. The following adverse reactions were reported:</paragraph>
                        <table ID="a37566d5-fac7-45b6-81f9-91ac0425437c" width="550">
                           <caption>Incidence of Adverse Reactions (%), N=58</caption>
                           <colgroup>
                              <col width="37%" align="left" valign="top"/>
                              <col width="24%" align="center" valign="top"/>
                              <col width="13%" align="center" valign="top"/>
                              <col width="13%" align="center" valign="top"/>
                              <col width="13%" align="center" valign="top"/>
                           </colgroup>
                           <thead>
                              <tr styleCode="First Last">
                                 <td styleCode="Lrule Rrule" align="left">   Adverse Reaction (AR)<footnote ID="K708">The number of individual adverse reactions reported does not necessarily reflect the number of individual subjects, since one subject could have multiple reporting of an adverse reaction.</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center"># of subjects (%)</td>
                                 <td styleCode="Rrule" align="center">Day 14</td>
                                 <td styleCode="Rrule" align="center">Day 28<footnote ID="K719">End of Treatment</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">Day 56<footnote ID="K724">Four Weeks Post Treatment</footnote>
                                 </td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" align="left">   Any AE</td>
                                 <td styleCode="Rrule" align="center">15 (26)</td>
                                 <td styleCode="Rrule" align="center">6 (10)</td>
                                 <td styleCode="Rrule" align="center">7 (12)</td>
                                 <td styleCode="Rrule" align="center">7 (12)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Telangiectasia</td>
                                 <td styleCode="Rrule" align="center">5 (9)</td>
                                 <td styleCode="Rrule" align="center">3 (5)</td>
                                 <td styleCode="Rrule" align="center">4 (7)</td>
                                 <td styleCode="Rrule" align="center">2 (4)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Erythema</td>
                                 <td styleCode="Rrule" align="center">3 (5)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">3 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Itching</td>
                                 <td styleCode="Rrule" align="center">3 (5)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">3 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Irritation</td>
                                 <td styleCode="Rrule" align="center">3 (5)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">3 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Burning</td>
                                 <td styleCode="Rrule" align="center">3 (5)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">3 (5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Hypopigmentation</td>
                                 <td styleCode="Rrule" align="center">2 (4)</td>
                                 <td styleCode="Rrule" align="center">2 (4)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Shiny skin</td>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Secondary atopic dermatitis</td>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Papules and pustules</td>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Keratosis pilaris</td>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Folliculitis</td>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Facial herpes simplex</td>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">   Acneiform eruption</td>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">   Ear infection</td>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center">1 (2)</td>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s06.2">
                     <id root="8f4c3f2f-5ed2-44e0-b0bc-bb6d1a06f9f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Clinical Studies Experience: Evaluation in Pediatric Subjects 3 months to 2 years old</title>
                     <text>
                        <paragraph>An open-label safety study was conducted in 29 children to assess the HPA axis by ACTH stimulation testing following use of fluocinolone acetonide topical oil, 0.01% twice daily for 4 weeks.  The following adverse reactions were reported in the study <content styleCode="italics">[See <linkHtml href="#s08.4">Use in Specific Populations (8.4)</linkHtml>]:</content>
                        </paragraph>
                        <table width="336" ID="ee7ea741-a46c-4a75-8ee8-1ff2e3339614">
                           <caption>Adverse Reactions (%), N=30<footnote ID="K983">Includes one subject who withdrew at Week 2</footnote>
                           </caption>
                           <col width="61%" align="left" valign="top"/>
                           <col width="39%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule">   Adverse Reaction</td>
                                 <td styleCode="Rrule"># of subjects (%)</td>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Diarrhea</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Vomiting</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Pyrexia</td>
                                 <td styleCode="Rrule">3 (10)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Abscess</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Molluscum</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Nasopharyngitis</td>
                                 <td styleCode="Rrule">2 (7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   URI</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Otitis media</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Cough</td>
                                 <td styleCode="Rrule">6 (20)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Rhinorrhea</td>
                                 <td styleCode="Rrule">4 (13)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Atopic dermatitis</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Eczema</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Hyperpigmentation</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">   Hypopigmentation</td>
                                 <td styleCode="Rrule">2 (7)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">   Rash</td>
                                 <td styleCode="Rrule">1 (3)</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s08">
               <id root="2f03dcaf-e9fe-4870-b684-ea11973e5512"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250423"/>
               <component>
                  <section ID="s08.1">
                     <id root="889edd63-b747-48e8-9d1c-89a59058ae44"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.</paragraph>
                        <paragraph>There are no adequate and well-controlled studies in pregnant women on teratogenic effects from fluocinolone acetonide topical oil, 0.01%. Therefore, fluocinolone acetonide topical oil, 0.01% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s08.3">
                     <id root="c07464fc-96e7-42b7-ac8d-5cec7fe36e44"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when fluocinolone acetonide topical oil, 0.01% is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s08.4">
                     <id root="48562191-a33f-4c25-aa33-d3007ecf876a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">8.4.1 Systemic Adverse Reactions in Pediatric Patients</content> HPA axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and subnormal response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.</paragraph>
                        <paragraph>Because of a higher ratio of skin surface area to body mass, children are at a greater risk for systemic adverse reactions than are adults when treated with topical corticosteroids. <content styleCode="italics">[See <linkHtml href="#s05.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">8.4.2 Evaluation in Peanut-Sensitive Pediatric Subjects</content> A clinical study was conducted to assess the safety of fluocinolone acetonide topical oil, 0.01%, which contains refined peanut oil, on subjects with known peanut allergies. The study enrolled 13 subjects with atopic dermatitis, 6 to 17 years of age. Of the 13 subjects, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The study evaluated the subjects’ responses to both prick test and patch test utilizing peanut oil NF, fluocinolone acetonide topical oil, 0.01% and histamine/saline controls. Subjects were also treated with fluocinolone acetonide topical oil, 0.01% twice daily for 7 days. Prick test and patch test results for all 13 patients were negative to fluocinolone acetonide topical oil, 0.01% and the refined peanut oil. One of the 9 peanut-sensitive patients experienced an exacerbation of atopic dermatitis after 5 days of fluocinolone acetonide topical oil, 0.01%. The bulk peanut oil NF, used in fluocinolone acetonide topical oil, 0.01% is heated between 232˚C – 246˚C (450˚F – 475˚F) for at least 15 minutes, which should provide for adequate decomposition of allergenic proteins. <content styleCode="italics">[See <linkHtml href="#s11">Description (11)</linkHtml>]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">8.4.3 Evaluation in Pediatric Subjects 2 to 6 years old</content> Open-label safety studies were conducted on 33 children (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable atopic dermatitis. Subjects were treated with fluocinolone acetonide topical oil, 0.01% twice daily for 4 weeks. Baseline body surface area involvement was 50% to 75% in 15 subjects and greater than 75% in 18 subjects. Morning pre-stimulation cortisol and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pre-stimulation cortisol levels (3.2 to 6.6 µg/dL; normal: cortisol &gt; 7 µg/dL) but all had normal responses to 0.25 mg of ACTH stimulation (cortisol &gt; 18 µg/dL).</paragraph>
                        <paragraph>
                           <content styleCode="bold">8.4.4 Evaluation in Pediatric Subjects 3 months to 2 years old</content> An open-label safety study was conducted in 29 children (7 subjects ages 3 to 6 months, 7 subjects ages &gt; 6 to 12 months and 15 subjects ages &gt; 12 months to 2 years of age) to assess the HPA axis by ACTH stimulation testing following use of fluocinolone acetonide topical oil, 0.01% twice daily for 4 weeks. All subjects had moderate to severe atopic dermatitis with disease involvement on at least 20% body surface area. Baseline body surface area involvement was 50% to 75% in 11 subjects and greater than 75% in 7 subjects. Morning pre-stimulation and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. All subjects had normal responses to 0.125 mg of ACTH stimulation (cortisol &gt;18 µg/dL).</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s10">
               <id root="d7e62b75-5b8c-4429-914d-779fc635d4b6"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects, including under conditions of normal use. <content styleCode="italics">[See <linkHtml href="#s05.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#s08.4">Use in Specific Populations (8.4)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="8dbcf90a-0e22-49bc-b126-f4959d711116"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Fluocinolone Acetonide Topical Oil, 0.01% (Body Oil) contains fluocinolone acetonide [(6α, 11β, 16α)-6,9-difluoro-11,21-dihydroxy-16,17[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione, cyclic 16,17 acetal with acetone], a synthetic corticosteroid for topical dermatologic use. Chemically, fluocinolone acetonide is C<sub>24</sub>H<sub>30</sub>F<sub>2</sub>O<sub>6</sub>. It has the following structural formula:</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="La704ed69-bf40-4808-bb26-3ce55caf5de0"/>
                  </paragraph>
                  <paragraph>
                     <content>Fluocinolone acetonide in fluocinolone acetonide topical oil, 0.01% has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water.</content>
                  </paragraph>
                  <paragraph>Each gram of fluocinolone acetonide topical oil, 0.01% contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2 and refined peanut oil NF.</paragraph>
                  <paragraph>Fluocinolone acetonide topical oil, 0.01% is formulated with 48% refined peanut oil NF. Physicians should use caution in prescribing fluocinolone acetonide topical oil, 0.01% for peanut-sensitive individuals.</paragraph>
               </text>
               <effectiveTime value="20250423"/>
               <component>
                  <observationMedia ID="La704ed69-bf40-4808-bb26-3ce55caf5de0">
                     <text>structure.jpg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s12">
               <id root="7cc4bbb3-761d-450f-8bcf-a3a330ec216a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250423"/>
               <component>
                  <section ID="s12.1">
                     <id root="7c21e8f4-8eb8-45d0-b274-3889743fe6b3"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Like other topical corticosteroids, fluocinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
               <component>
                  <section ID="s12.3">
                     <id root="e7b89e3b-7952-4f97-af40-c22fe44d2d50"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may increase percutaneous absorption. The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids may be necessary due to the fact that circulating levels are often below the level of detection. Once absorbed through the skin, topical corticosteroids are metabolized primarily in the liver, and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile.</paragraph>
                        <paragraph>Fluocinolone acetonide topical oil, 0.01% is in the low to medium range of potency as compared with other topical corticosteroids in vasoconstrictor studies.</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s13">
               <id root="41cf232a-ff3d-4945-a14c-485ccbcc5715"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250423"/>
               <component>
                  <section ID="s13.1">
                     <id root="394b6dc8-0c37-4eea-9d16-49905c6cdc1e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, mutagenesis, impairment of fertility</title>
                     <text>
                        <paragraph>Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of fluocinolone acetonide topical oil, 0.01%. Studies have not been performed to evaluate the mutagenic potential of fluocinolone acetonide, the active ingredient in fluocinolone acetonide topical oil, 0.01%. Some corticosteroids have been found to be genotoxic in various genotoxicity tests (i.e. the <content styleCode="italics">in vitro</content> human peripheral blood lymphocyte chromosome aberration assay with metabolic activation, the<content styleCode="italics"> in vivo </content>mouse bone marrow micronucleus assay, the Chinese hamster micronucleus test, and the <content styleCode="italics">in vitro</content> mouse lymphoma gene mutation assay).</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="966e293a-90d3-4e14-aa12-573d359f9bee"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Fluocinolone Acetonide Topical Oil, 0.01% is supplied in bottles containing 4 fluid ounces. It is labeled as Body Oil <content styleCode="bold">(NDC #64980-331-04).</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250423"/>
               <component>
                  <section>
                     <id root="381b4aa2-cbcd-407a-b9f8-fb731188cec0"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Storage: Store at 25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s17">
               <id root="dcd5b520-e02c-4532-ad71-fc80f8873092"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20250423"/>
               <component>
                  <section ID="s17.1">
                     <id root="ab3a8b00-a71e-4f01-9f27-af29a96948ac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1 Instructions</title>
                     <text>
                        <list listType="unordered">
                           <item>Fluocinolone acetonide topical oil, 0.01% should be used as directed by the physician. It is for external use only. Avoid contact with the eyes. In case of contact, wash eyes liberally with water.</item>
                           <item>Fluocinolone acetonide topical oil, 0.01% should not be used for any disorder other than that for which it was prescribed.</item>
                           <item>Patients should report any worsening of their skin condition to their physician promptly.</item>
                           <item>Fluocinolone acetonide topical oil, 0.01% should not be applied under occlusion unless directed by the physician. Fluocinolone acetonide topical oil, 0.01% should not be applied to the diaper area as diapers or plastic pants may constitute occlusive use.</item>
                           <item>Fluocinolone acetonide topical oil, 0.01% should not be used on the face, axillae, or groin unless directed by the physician.</item>
                           <item>As with other corticosteroids, therapy should be discontinued when control of disease is achieved. Contact the physician if no improvement is seen within 2 weeks.</item>
                           <item>Do not use other corticosteroid-containing products while using fluocinolone acetonide topical oil, 0.01% without first consulting your physician.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250423"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s18">
               <id root="d9e5c7f0-51b0-4413-b7d1-d407586543ac"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>Lyne Laboratories, Inc.<br/>Brockton, MA 02301</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                  </paragraph>
                  <paragraph>Rising Pharma Holdings, Inc.<br/>East Brunswick, NJ 08816</paragraph>
                  <paragraph>
                     <content styleCode="bold">Revised:</content> 04/2025</paragraph>
                  <paragraph>PIR33104-00</paragraph>
               </text>
               <effectiveTime value="20250423"/>
            </section>
         </component>
         <component>
            <section ID="s19">
               <id root="cd0d458e-a4a0-4fd6-b49e-c1a8c39b680a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>———PRINCIPAL DISPLAY PANEL———<br/>
                     <br/>Rising®<br/>NDC 64980-331-04<br/>
                     <br/>Fluocinolone<br/>Acetonide<br/>Topical Oil,<br/>0.01%<br/>(Body Oil)<br/>
                     <br/>FOR TOPICAL USE ONLY<br/>NOT FOR ORAL,<br/>OPHTHALMIC,<br/>or INTRAVAGINAL USE<br/>
                     <br/>SHAKE WELL BEFORE USE<br/>
                     <br/>Net Contents<br/>118.28 mL<br/>(4 fl. oz.)                   Rx only</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="L53d4be40-9f9e-4cfc-8c6d-6476742e8ed7"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250423"/>
               <component>
                  <observationMedia ID="L53d4be40-9f9e-4cfc-8c6d-6476742e8ed7">
                     <text>carton-label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>